Karos Pharmaceuticals Information

View Top Employees from Karos Pharmaceuticals

Karos Pharmaceuticals is a privately held, clinical-stage biopharmaceutical company advancing innovative medicines for patients living with rare diseases, including fibrotic, inflammatory, and metabolic diseases. Karos' lead clinical candidate, KAR5585, is completing Phase 1 testing for the treatment of pulmonary arterial hypertension (PAH). KAR5585 also is being studied in preclinical research for the treatment of pulmonary hypertension unrelated to PAH. A next-generation TPH1 inhibitor also is being advanced for the treatment of carcinoid syndrome. The Karos leadership team and scientific staff have extensive R&D experience and collaborate closely with key opinion leaders and experts in rare diseases with significant medical needs. Karos is supported by leading life science investor New Leaf Venture Partners.

Website	http://www.karospharma.com
Revenue	$4 million
Employees	1 (1 on RocketReach)
Founded	2009
Address	5 Science Park # 2, New Haven, Connecticut 06511, US
Phone	+1 203-535-0540
Industry	Pharmaceuticals, Drug Manufacturing & Research, Biotechnology, Drug Discovery, Science and Engineering, Healthcare, Medical, Health Care, Pharmaceutical
Keywords	Biopharmaceutical, Rare Diseases, Clinical Stage, Innovative Medicines, Biotechnology, Fibrotic Diseases, Inflammatory Diseases, Clinical Trials, Metabolic Diseases, Drug Development, Pharmaceutical Research, Therapeutics, Preclinical Development, Drug Discovery, New Treatments, Patient Care, Healthcare
Competitors	Regeneron, Moderna Therapeutics, Vertex Pharmaceuticals, Genentech, Sage Therapeutics, Amgen, Lilly India, AstraZeneca, Pfizer, Johnson & Johnson +40 more (view full list)
SIC	SIC Code 2834 Companies, SIC Code 28 Companies, SIC Code 283 Companies
NAICS	NAICS Code 3254 Companies, NAICS Code 325 Companies, NAICS Code 32541 Companies, NAICS Code 32 Companies